Canada markets closed

Eliem Therapeutics, Inc. (ELYM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.46-0.49 (-5.47%)
At close: 04:00PM EDT
8.46 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close8.95
Open9.18
Bid8.43 x 400
Ask8.53 x 200
Day's Range8.33 - 9.54
52 Week Range2.34 - 11.55
Volume167,790
Avg. Volume856,438
Market Cap248.96M
Beta (5Y Monthly)-0.35
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

    Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Co

  • GlobeNewswire

    Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

    SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in